Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook 🐍 Open ➽ www.pdfvce.com 🢪 enter ➡ JN0-281 ️⬅️ and obtain a free download 🔮Valid Exam JN0-281 Book

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis

09/27/2021

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ — Innovent Biologics, Group. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial (clinicaltrials.gov,…

Read More

Chest x-rays in the ER predict COVID-19 severity

05/20/2020

Excerpt from the Article: “The study findings demonstrate x-ray’s value in helping physicians identify, triage, and treat high-risk patients, wrote a team led by Dr. Danielle Toussie of Mount Sinai Hospital in New York City. “We demonstrate how valuable x-rays can be during this pandemic because, by evaluating disease in different portions of the lungs, we…

Read More

ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

06/01/2020

Excerpt from the article: “TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to…

Read More

4D-Fueled AI with DCE-MRI Improves Breast Lesion Characterization

03/08/2021

Excerpt from the Article: Radiologists can classify breast lesions more accurately if they use artificial intelligence algorithms fueled by 4D data captured with dynamic contrasted-enhanced MRI (DCE-MRI), new research has found. In a study published on Feb. 24 in Radiology: Artificial Intelligence, investigators from the University of Chicago outlined their method for fusing the 4D…

Read More

Request A Demo

03/20/2020

Schedule Your Personalized Demonstration! You’ll be Amazed By TrialStat With TrialStat your studies will run smoothly, on-time and within budget. Your Study Coordinators will enjoy the intuitive user interface and the speed in which they can enter their data. Submit the form, below and our team will reach out to you to schedule your personalized…

Read More

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

07/15/2022

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China  , July 3, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe active ulcerative colitis…

Read More

Inspiring Women Transforming Science

01/09/2024

“Equity and representation in science matter more than ever, and the Rosalind Franklin Society continues its mission to recognize, foster, and advance the critical contributions of women and underrepresented minorities in science. Our annual year-end conference highlights the innovators and changemakers with unique experiences and leadership.” To learn more about this incredible event and to register for…

Read More

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

04/14/2022

Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type. BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer.  BriaCell to present Bria-OTS™ approach at the American Association for Cancer Research (AACR) Annual Meeting 2022. Excerpt from the…

Read More

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

01/11/2023

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing…

Read More

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

01/06/2022

HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response Excerpt from the Press Release: MENLO PARK, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced…

Read More